PRRSV NSP2 hijacks host lipophagy via a LIPE-PNPLA2-AMPK-MTOR axis to promote viral replication

Porcine Reproductive and Respiratory Syndrome Virus (PRRSV) is one of the most economically devastating swine pathogens worldwide, and this study uncovers a new molecular trick it uses to hijack the cell's own recycling machinery. The viral protein NSP2 was found to activate a process called lipophagy — a selective form of autophagy where the cell digests its own fat droplets (lipid droplets) — in order to fuel viral replication. Specifically, NSP2 triggers a signaling cascade involving two lipid-mobilizing enzymes (LIPE and PNPLA2), which activates the energy-sensing protein AMPK while simultaneously suppressing MTOR, the cell's main brake on autophagy. By commandeering this LIPE-PNPLA2-AMPK-MTOR axis, the virus essentially forces the cell to break down its lipid stores, providing the fatty acid building blocks that PRRSV needs to build new viral membranes and replicate efficiently. This represents a sophisticated form of metabolic parasitism: the virus does not merely tolerate autophagy but actively redirects a selective branch of it toward its own benefit. The findings reveal that lipophagy, not just general autophagy, plays a specific pro-viral role in PRRSV infection. Understanding this mechanism may point toward host-directed antiviral strategies that disrupt lipid metabolism without broadly suppressing autophagy, which would be too toxic. More broadly, it illustrates how pathogens can exploit selective autophagy pathways that are normally central to cellular energy homeostasis.

• PRRSV NSP2 directly activates lipophagy (selective autophagic degradation of lipid droplets) to support viral replication, identifying NSP2 as the key viral effector driving this process.
• NSP2-driven lipophagy operates through a defined LIPE-PNPLA2-AMPK-MTOR signaling axis: upregulation of lipases LIPE and PNPLA2 activates AMPK and suppresses MTOR, thereby releasing the brake on autophagic flux.
• Disrupting this axis — by inhibiting LIPE, PNPLA2, or AMPK, or by reactivating MTOR — was reported to impair viral replication, establishing the pathway as functionally required for PRRSV propagation rather than merely correlative.

This is a molecular virology study (likely in vitro and/or in vivo porcine cell models) investigating the mechanistic role of the PRRSV non-structural protein NSP2 in lipophagy regulation. The experimental approach involved overexpression and knockdown/knockout of LIPE, PNPLA2, AMPK, and MTOR components in PRRSV-infected cells, combined with lipid droplet imaging, autophagic flux assays, and viral replication quantification. Specific sample sizes, cell lines, and animal model details are not resolvable from the abstract alone; full methodological confidence requires access to the primary manuscript. Study design appears mechanistic rather than epidemiological, with no clinical follow-up component.

Because this study is conducted in a viral infection context with a swine-specific pathogen, the degree to which the LIPE-PNPLA2-AMPK-MTOR lipophagy axis generalizes to other viruses, other selective autophagy substrates, or human disease settings remains unclear. The study likely relies on cell culture or porcine tissue models, so in vivo pharmacological validation in intact animals with antiviral endpoints has yet to be demonstrated. A critical next experiment would be to test whether small-molecule inhibitors of LIPE or PNPLA2 reduce PRRSV burden in live pigs without causing metabolic toxicity from impaired physiological lipid homeostasis. Additionally, it is unknown whether NSP2's lipophagy-activating function is shared by related arterivirus NSP2 homologs, which would broaden or narrow the translational relevance of these findings.

This study extends [§38] (Mammalian Lysophagy) by demonstrating that selective autophagy subtypes beyond lysophagy can be specifically hijacked by pathogens through discrete molecular axes, reinforcing the emerging view that cargo-selective autophagy pathways have distinct regulatory logic exploitable by infectious agents. It parallels [§37] (CHCHD2/CHCHD10 and autophagic clearance via GABARAPs) in the sense that both articles reveal how specific molecular effectors — viral or mitochondrial — can redirect selective autophagy flux toward defined substrates, here lipid droplets rather than protein aggregates. The AMPK-MTOR axis central to this paper directly connects to metabolic autophagy regulation discussed in [§39] (Metformin-phytochemical combinations in steatotic liver disease), where AMPK activation by metformin promotes autophagic lipid clearance in a therapeutic context — providing an instructive contrast: the same AMPK-MTOR logic that benefits the host in metabolic disease is here co-opted to benefit the virus. The lipid-droplet-focused mechanism also contextualizes findings in [§39] regarding hepatic lipophagy, suggesting that the LIPE-PNPLA2 node identified here may be a generalizable regulatory entry point into lipophagic flux beyond the viral setting.

• Mammalian Lysophagy: mechanisms and pathophysiological implications
  Directly covers mammalian selective autophagy of membrane-bound organelles (lysophagy); comparing mechanisms reveals shared versus divergent regulatory logic between lysophagy and the lipophagy axis described here.
• Metformin-phytochemical combination therapy in metabolic dysfunction-associated steatotic liver disease: mechanistic insights and therapeutic potential
  Examines AMPK-MTOR-driven lipid autophagy in a metabolic liver disease context; the same signaling axis runs in both studies but with opposite valence — therapeutic in MASLD, pro-viral in PRRSV infection.
• CHCHD2 and CHCHD10 promoted autophagic clearance of protein aggregates via GABARAPs
  Shows cargo-selective autophagy directed by specific protein effectors (CHCHD2/CHCHD10 via GABARAPs), providing a structural parallel to NSP2 acting as a selective-autophagy effector for lipid droplets.
• Phase 3 Trial of eRapa in Patients With Familial Adenomatous Polyposis
  Phase 3 trial of eRapa (rapamycin derivative) targeting MTOR in FAP; relevant because pharmacological MTOR inhibition is the downstream effector in the NSP2 axis, and this trial illustrates the clinical ceiling and toxicity profile of systemic MTOR suppression.